Qizheng Tibetan Medicine released its 2026 interim report. Net profit attributable to the parent in the first half was 371 million yuan, up 3.6% year on year. Operating revenue was 978 million yuan, down 16.8% year on year. Net profit attributable to the parent excluding non-recurring items was 300 million yuan, up 3.6% year on year. Net operating cash flow was 239 million yuan, down 51.3% year on year. In the second quarter, operating revenue was 573 million yuan, down 25.8% year on year, and net profit attributable to the parent was 276 million yuan, down 2.3% year on year. The company said industry development conditions are relatively positive, with industrial policies and regulatory details from multiple ministries being rolled out one after another, providing support for the transformation and development of the traditional Chinese medicine industry. The company continues to maintain its leading position in the Tibetan medicine market.
Tibet Cheezheng Tibetan Medicine Co LtdNet profit up 3.6% but revenue down 16.8% and cash flow down 51.3%, mixed results.
